ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA.

10/02/2026, 2:55 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in XTI Aerospace, Inc. of Class Action Lawsuit and Upcoming Deadlines – XTIA

Pomerantz Law Firm has filed class action lawsuits against XTI Aerospace, Baidu, and Ardelyx for alleged securities fraud and unlawful business practices. XTI Aerospace experienced a significant stock price decline of 15.92% following disclosure of an internal review of its former CEO who resigned on August 17, 2026. Investors have until October 27, 2026, to request Lead Plaintiff status.

09/29/2026, 4:58 PM • GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx, Inc. (NASDAQ: ARDX) investors who purchased stock between January 13, 2025 and August 6, 2026. The lawsuit alleges that defendants made materially false and misleading statements about the company's commercial performance and growth prospects for drugs XPHOZAH and IBSRELA, while concealing information about payer-related access barriers, prior authorization requirements, and step edit requirements that hindered patient access and new-patient starts. The deadline to serve as lead plaintiff is November 16, 2026.

09/25/2026, 9:12 PM • GlobeNewswire

ARDX Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardelyx, Inc. Securities Class Action Lawsuit

Robbins LLP reminds investors of the November 16, 2026 lead plaintiff deadline in a securities class action against Ardelyx, Inc. (ARDX). The lawsuit alleges the company misled investors about commercial performance and growth prospects for its drugs ISBRELA and XPHOZAH, concealing material adverse facts about payer access barriers and reimbursement challenges. On August 6, 2026, Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.

09/25/2026, 3:35 PM • GlobeNewswire

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations under the Securities Exchange Act of 1934. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers that impacted patient access to its drugs XPHOZAH and IBSRELA, causing delays in new-patient starts and prescription fulfillment. The class period runs from January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.

09/25/2026, 10:48 AM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx, Inc. investors who purchased stock between January 13, 2025 and August 6, 2026. The lawsuit alleges that Ardelyx provided materially false and misleading statements regarding commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA, while concealing information about payer access barriers, prior authorization requirements, and step edit requirements that hindered patient access and prescription fulfillment. Investors who wish to serve as lead plaintiff must file by November 16, 2026.

09/22/2026, 8:54 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Ardelyx, Inc. alleging that the company made false and misleading statements regarding its commercial performance and growth prospects for drugs XPHOZAH and IBSRELA. The complaint claims Ardelyx failed to disclose increasing payer-related access barriers, stringent prior authorization requirements, and negative impacts on patient access and commercial performance during the class period from January 13, 2025 to August 6, 2026.

09/22/2026, 12:00 PM • GlobeNewswire

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. (ARDX)

A securities class action lawsuit has been filed against Ardelyx, Inc. for allegedly providing misleading statements about its commercial performance while concealing material adverse facts regarding payer access barriers and reimbursement issues for XPHOZAH and IBSRELA. The company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance on August 6, 2026, causing the stock to decline approximately 18% in a single day.

09/18/2026, 3:23 PM • GlobeNewswire

ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026

Faruqi & Faruqi, LLP is investigating securities fraud claims against Ardelyx (NASDAQ: ARDX) for allegedly misleading investors about commercial performance of drugs XPHOZAH and IBSRELA and failing to disclose payer access barriers. The company reduced 2026 IBSRELA revenue guidance and withdrew XPHOZAH long-term guidance on August 6, 2026, causing stock to drop 18% in one day. Investors who purchased securities between January 13, 2025 and August 6, 2026 may be eligible to participate in the class action with a November 16, 2026 deadline to seek lead plaintiff status.

09/18/2026, 1:53 PM • GlobeNewswire

New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff

A new analysis by Spherix Global Insights reveals that access barriers, not efficacy issues, are limiting Xphozah (tenapanor) uptake in the dialysis hyperphosphatemia market. Nephrologists report they would nearly triple Xphozah use without reimbursement and coverage obstacles. However, the drug faces persistence challenges with gastrointestinal tolerability causing discontinuation rates to double to 8%. The findings also show physicians significantly overestimate phosphorus control and combination therapy use among patients. As the TDAPA reimbursement program expires at the end of 2026, phosphate-lowering therapies will face a flattened competitive landscape.

07/29/2026, 10:46 AM • GlobeNewswire

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Ardelyx President and CEO Michael Raab sold 41,666 shares worth approximately $243,000 on March 16, 2026, as part of a routine 10b5-1 trading plan. The sale represented 2.21% of his holdings and followed an option exercise. Despite recent legal headwinds abating and a new chief medical officer appointment, the stock is down 16.57% over five years, though analysts have a $16.10 price target suggesting 170% upside potential.

04/03/2026, 11:11 AM • The Motley Fool

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Ardelyx, Inc. announced the appointment of Dr. Rajani Dinavahi as Chief Medical Officer. Dr. Dinavahi brings over two decades of healthcare and biotechnology experience, including leadership roles at Atara Biotherapeutics and Amgen. She will lead medical capabilities and pipeline advancement for the commercial-stage biopharmaceutical company.

04/01/2026, 8:01 AM • GlobeNewswire

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Ardelyx, Inc. announced it will hold a conference call on February 19, 2026, to discuss full year and fourth quarter 2025 financial results and provide a business update. The call will feature commentary from executive leadership including CEO Mike Raab and CFO Sue Hohenleitner. The company has two FDA-approved commercial products (IBSRELA and XPHOZAH) and is advancing IBSRELA in Phase 3 development for chronic idiopathic constipation.

02/05/2026, 8:00 AM • GlobeNewswire

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

The biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech sector by 2035. Key catalysts include FDA approvals, clinical trial progress, and record revenue achievements across multiple therapeutic areas including diabetes, kidney disease, and rare genetic disorders.

01/23/2026, 12:56 PM • GlobeNewswire